Last reviewed · How we verify
19560 Rp (METAPRAMINE)
19560 Rp (generic name: METAPRAMINE) is a metapramine drug. It is currently in Phase 2 development.
Metapramine is thought to work by interacting with certain receptors in the brain to produce its therapeutic effects.
Metapramine, a small molecule drug in the metapramine class, is a medication with unknown target and commercial status. Its mechanism of action is not well-documented, and it is not approved by the FDA for any indications. As a result, there is limited information available on its use, efficacy, and safety profile. Further research is needed to fully understand the properties and potential applications of metapramine. Due to the lack of available data, it is not possible to provide a comprehensive summary of this medication.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | METAPRAMINE |
|---|---|
| Drug class | metapramine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain is like a computer, and metapramine is a software update that helps fix problems with how the computer is working. It does this by sending signals to the brain's receptors, which are like special buttons that receive and process information. By adjusting the way these receptors work, metapramine can help alleviate symptoms of certain conditions.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 19560 Rp CI brief — competitive landscape report
- 19560 Rp updates RSS · CI watch RSS
Frequently asked questions about 19560 Rp
What is 19560 Rp?
How does 19560 Rp work?
What is the generic name of 19560 Rp?
What drug class is 19560 Rp in?
What development phase is 19560 Rp in?
Related
- Drug class: All metapramine drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing